摘要
目的探讨血脂康胶囊治疗原发性高血压左室肥厚（LVH）合并高脂血症患者的临床疗效。方法选取2012年6月~2014年5月我院就诊的原发性高血压LVH合并高脂血症患者120例,随机分为观察组和对照组,每组60例。两组患者均给予钙拮抗剂（CCB）和（或）血管紧张素转化酶抑制剂（ACEI）常规抗高血压治疗。观察组患者在常规抗高血压治疗的基础上加血脂康胶囊口服0.6 g,2次/d,连服12个月。观察两组患者血压、血脂（TG、TC、HDL-C、LDL-C）指标、左室重量指数（LVMI）及药物不良反应。结果治疗12个月后,观察组和对照组血压均较治疗前明显下降（P〈0.05）。观察组治疗后LVMI、TG、TC和LDL-C均明显降低,HDL-C明显升高（P〈0.05）;对照组仅LVMI在治疗后降低,而TG、TC、LDL-C和HDL-C治疗前后差异无统计学意义（P〉0.05）;且治疗后观察组LVMI值为（120.38±15.53）g/m2,低于对照组的（132.32±14.85）g/m2（P〈0.05）。两组均未出现严重不良反应。结论血脂康胶囊能有效降低血脂水平,逆转心肌肥厚,改善患者预后。
Objective To observe the effect of the treatment of xuezhikang capsule on patients with essential hypertension combined with left ventricular hypertrophy（LVH） and hyperlipidemia.. Methods A total of 120 patients with essential hypertension LVH combined with hyperlipidemia who had been treated in our hospital from Jun 2012 to May2014 were selected and then randomly divided into observation group and control group,with 60 patients in each group.All patients were administered conventional antihypertensive therapy（CCB,ACEI,CCB combinde with ACEI）.The observation group was given xuezhikang capsule,twice daily,0.6 g one time.After continuous treatment for 12 months,the blood pressure,the blood lipid levels（TG,TC,HDL-C,LDL-C） and left ventricular mass index（LVMI） were measured before and after treatment.The adverse reactions of medicine in two groups were observed. Results After 12 months treatment,the blood pressure was significantly lower in two groups than before treatment（P 〈0.05）.The LVMI,TG,TC and LDL-C in observation group was significantly lower than before treatment respectively,while HDL-C was significantly improved after treatment（P〈0.05）.The score of LVMI in treatment group was（120.38±15.53） g/m2,which was lower than observation group（132.32±14.85） g/m2 after 12 months treatment（P〈0.05）.But there was no significant difference in TG,TC,LDL-C and HDL-C before and after treatment（P〉0.05）.There were no serious adverse reactions that found in the two groups. Conclusion Xuezhikang capsule can further reverse myocardial hypertrophy and improve the level of blood lipid and the quality of life of patients with essential hypertension combined with LVH and hyperlipidemia.
出处
《中国当代医药》
2016年第1期38-41,共4页
China Modern Medicine
关键词
原发性高血压
高脂血症
血脂康
左室重构
Essential hypertension
Hyperlipemia
Xuezhikang
Left ventricular remodeling
